Johnson & Johnson has reported new phase 3 data with its FcRn blocker nipocalimab in generalised myasthenia gravis (gMG), pointing to data that it says differentiates it from other drugs in the class.
Novo Nordisk’s GLP-1 agonist Ozempic has shown efficacy in yet another indication, achieving a 24% reduction in kidney disease-related events in people with type 2 diabetes and chronic kidney disease ...
Jiaying This is The English We Speak from BBC Learning English and we’re talking about the phrase ‘another string to your bow’ which describes having an additional skill to use if the first skill ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback